Table 1.
Patients baseline characteristics (safety/ITT population)
| BMV dressing (N = 165) | CBD ointment (N = 159) | |
|---|---|---|
| Age (years), mean (SD) | 47.5 (14.6) | 46.7 (13.6) |
| Male/Female (%) | 61.8/38.2 | 62.3/37.7 |
| Psoriasis total surface area (cm2) | ||
| Mean (SD) | 162.8 (170.2) | 176.8 (208.3) |
| Median (range) | 106.0 (17.3–1132.0) | 111.0 (23.0–1132.0) |
| Target lesions surface area (cm2) | ||
| Mean (SD) | 76.0 (51.1) | 72.5 (45.0) |
| Median (range) | 66.5 (10.0–288.0) | 65.0 (20.7–230.0) |
| Target lesions localization (% patients) | ||
| Elbow | 49.7% | 49.1% |
| Knee | 11.5% | 10.1% |
| Elbow and knee | 38.8% | 40.9% |
| Total TSS-4 | ||
| Mean (SD) | 6.70 (1.48) | 6.61 (1.51) |
| Median (range) | 7.00 (4.0–11.0) | 6.50 (4.0–10.5) |
| Total TSS-3 | ||
| Mean (SD) | 4.73 (1.58) | 4.44 (1.43) |
| Median (range) | 4.75 (0.0–8.25) | 4.50 (1.0–8.0) |
| PGA score, assessed by | ||
| Investigator | ||
| Mean (SD) | 3.08 (0.64) | 3.08 (0.68) |
| Median (range) | 3.00 (1.0–5.0) | 3.00 (1.0–5.0) |
| Patient | ||
| Mean (SD) | 2.97 (0.91) | 2.92 (1.11) |
| Median (range) | 3.00 (−2.0–5.0) | 3.00 (−2.0–5.0) |
| Total DLQI | ||
| Mean (SD) | 8.58 (5.94) | 8.52 (5.89) |
| Median (range) | 8.00 (0.0–26.0) | 7.00 (0.0–25.0) |
BMV, betamethasone valerate dressing; CBD, calcipotriol–betamethasone dipropionate ointment; DLQI, dermatology life quality index; PGA, psoriasis global assessment; ITT, intention to treat; TSS, total severity score.